Toll-like receptor agonists are they good adjuvants? Journal Article

Authors: Gnjatic, S.; Sawhney, N. B.; Bhardwaj, N.
Article Title: Toll-like receptor agonists are they good adjuvants?
Abstract: Therapeutic immunization leading to cancer regression remains a significant challenge. Successful immunization requires activation of adaptive immunity, including tumor specific CD4+ T cells and CD8+ T cells. Generally, the activation of T cells is compromised in patients with cancer because of immune suppression, loss of tumor antigen expression, and dysfunction of antigen-presenting cells. Antigen-presenting cells such as dendritic cells (DCs) are key for the induction of adaptive antitumor immune responses. Recently, attention has focused on novel adjuvants that enhance dendritic cell function and their ability to prime T cells. Agonists that target toll-like receptors are being used clinically either alone or in combination with tumor antigens and showing initial success both in terms of enhancing immune responses and eliciting antitumor activity. This review summarizes the application of these adjuvants to treat cancer and the potential for boosting responses in vivo. Copyright © Lippincott Williams & Wilkins.
Keywords: review; neoplasms; cd8+ t lymphocyte; dendritic cell; antineoplastic activity; tumor antigen; cancer regression; dendritic cells; cancer vaccine; cancer vaccines; cancer immunization; cd4+ t lymphocyte; adaptive immunity; adjuvants, immunologic; antigen presenting cell; t lymphocyte activation; toll-like receptors; vaccine adjuvants; toll like receptor agonist
Journal Title: The Cancer Journal
Volume: 16
Issue: 4
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2010-07-01
Start Page: 382
End Page: 391
Language: English
DOI: 10.1097/PPO.0b013e3181eaca65
PUBMED: 20693851
PROVIDER: scopus
PMCID: PMC2922045
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "CODEN: CAJOC" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Sacha Gnjatic
    111 Gnjatic